华仁药业
(300110)
| 流通市值：38.03亿 | | | 总市值：38.07亿 |
| 流通股本：11.81亿 | | | 总股本：11.82亿 |
| 报告期 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 303,472,326.57 | 1,353,161,818.05 | 1,073,621,963.53 | 771,461,220.59 |
| 营业收入 | 303,472,326.57 | 1,353,161,818.05 | 1,073,621,963.53 | 771,461,220.59 |
| 二、营业总成本 | 281,164,064.61 | 1,270,221,916.92 | 963,605,145.6 | 683,871,113.39 |
| 营业成本 | 193,321,530 | 876,827,399.28 | 686,062,998.89 | 480,197,503.72 |
| 税金及附加 | 5,807,361.63 | 23,006,253 | 16,729,467.9 | 11,734,734.15 |
| 销售费用 | 31,407,185.48 | 141,719,328.05 | 97,292,239.84 | 79,049,769.86 |
| 管理费用 | 22,566,975.77 | 101,527,341.14 | 70,658,208.71 | 47,461,195.38 |
| 研发费用 | 14,463,043.18 | 72,290,945.17 | 49,578,277.19 | 34,871,083.02 |
| 财务费用 | 13,597,968.55 | 54,850,650.28 | 43,283,953.07 | 30,556,827.25 |
| 其中:利息费用 | 11,207,061.64 | 54,316,994.26 | 40,691,109.84 | 27,542,486.84 |
| 其中:利息收入 | 137,696.69 | 929,470.83 | 525,294.73 | 419,697.42 |
| 加:投资收益 | -24,361.99 | -1,168,022.14 | 356,758.99 | 356,758.99 |
| 资产处置收益 | - | 16,471.15 | 5,673.96 | 5,673.96 |
| 资产减值损失(新) | -1,077,971.49 | -96,215,281.19 | -1,451,480.86 | -1,451,480.86 |
| 信用减值损失(新) | -6,998,760.8 | -1,352,920,181.36 | -913,335.01 | -5,581,611.97 |
| 其他收益 | 3,055,811.34 | 14,355,568.1 | 8,866,179.69 | 7,431,558.94 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 17,262,979.02 | -1,352,991,544.31 | 116,880,614.7 | 88,351,006.26 |
| 加:营业外收入 | 2,118,208.88 | 127,503.15 | 582,194.48 | 241,732.16 |
| 减:营业外支出 | 1,123,891.84 | 2,890,089.65 | 3,052,073.1 | 1,460,340.41 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 18,257,296.06 | -1,355,754,130.81 | 114,410,736.08 | 87,132,398.01 |
| 减:所得税费用 | 1,710,667.02 | 7,078,043.06 | 13,939,611.92 | 10,417,750.59 |
| 六、净利润 | 16,546,629.04 | -1,362,832,173.87 | 100,471,124.16 | 76,714,647.42 |
| 持续经营净利润 | 16,546,629.04 | -1,362,832,173.87 | 100,471,124.16 | 76,714,647.42 |
| 归属于母公司股东的净利润 | 16,028,449.64 | -1,368,478,968.49 | 95,530,954.43 | 73,213,045.8 |
| 少数股东损益 | 518,179.4 | 5,646,794.62 | 4,940,169.73 | 3,501,601.62 |
| (一)基本每股收益 | 0.01 | -1.16 | 0.08 | 0.06 |
| (二)稀释每股收益 | 0.01 | -1.16 | 0.08 | 0.06 |
| 九、综合收益总额 | 16,546,629.04 | -1,362,832,173.87 | 100,471,124.16 | 76,714,647.42 |
| 归属于母公司股东的综合收益总额 | 16,028,449.64 | -1,368,478,968.49 | 95,530,954.43 | 73,213,045.8 |
| 归属于少数股东的综合收益总额 | 518,179.4 | 5,646,794.62 | 4,940,169.73 | 3,501,601.62 |
| 公告日期 | 2025-04-23 | 2025-04-23 | 2024-10-29 | 2024-08-30 |
| 审计意见(境内) | | 标准无保留意见 | | |